GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease

[1] Kosmalski M., Ziółkowska S., Czarny P., Szemraj J., Pietras T.: The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus. J Clin Med., 2022; 11: 1375 KosmalskiM. ZiółkowskaS. CzarnyP. SzemrajJ. PietrasT. The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus J Clin Med 2022 11 1375 Search in Google Scholar

[2] Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.C., Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol., 2013; 58: 593–608 BlachierM. LeleuH. Peck-RadosavljevicM. VallaD.C. Roudot-ThoravalF. The burden of liver disease in Europe: a review of available epidemiological data J Hepatol 2013 58 593 608 Search in Google Scholar

[3] Younossi Z. M., Golabi P., de Avila L., Paik J. M., Srishord M., Fukui N., Qiu Y., Burns L., Afendy A., & Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol., 2019; 71: 793–801 YounossiZ. M. GolabiP. de AvilaL. PaikJ. M. SrishordM. FukuiN. QiuY. BurnsL. AfendyA. NaderF. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis J Hepatol 2019 71 793 801 Search in Google Scholar

[4] Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006; 368: 1696–705 DruckerD.J. NauckM.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes The Lancet 2006 368 1696 705 Search in Google Scholar

[5] Filippatos T.D., Panagiotopoulou T.V., Elisaf M.S.. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud RDS., 2014; 11: 202 FilippatosT.D. PanagiotopoulouT.V. ElisafM.S. Adverse effects of GLP-1 receptor agonists Rev Diabet Stud RDS 2014 11 202 Search in Google Scholar

[6] He Z., Gao Y., Lieu L., Afrin S., Cao J., Michael N.J., Dong Y., Sun J., Guo H., Williams K.W. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons—Implications for energy balance and glucose control. Mol Metab., 2019; 28: 120–134 HeZ. GaoY. LieuL. AfrinS. CaoJ. MichaelN.J. DongY. SunJ. GuoH. WilliamsK.W. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons—Implications for energy balance and glucose control Mol Metab 2019 28 120 134 Search in Google Scholar

[7] Wadden T.A., Hollander P., Klein S., Niswender K., Woo V., Hale P.M., Aronne L.; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes., 2013; 37: 1443–51 WaddenT.A. HollanderP. KleinS. NiswenderK. WooV. HaleP.M. AronneL. NN8022-1923 Investigators Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study Int J Obes 2013 37 1443 51 Search in Google Scholar

[8] Monami M., Dicembrini I., Marchionni N., Rotella C.M., Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res., 2012: 672658 MonamiM. DicembriniI. MarchionniN. RotellaC.M. MannucciE. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis Exp Diabetes Res 2012 672658 Search in Google Scholar

[9] Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al. STEP 1 Study Group: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med., 2021; 384: 989–1002 WildingJ.P.H. BatterhamR.L. CalannaS. DaviesM. Van GaalL.F. LingvayI. McGowanB.M. RosenstockJ. TranM.T.D. WaddenT.A. STEP 1 Study Group: Once-weekly semaglutide in adults with overweight or obesity N Engl J Med 2021 384 989 1002 Search in Google Scholar

[10] Davies M., Færch L., Jeppesen O.K., Pakseresht A., Pedersen S.D., Perreault L., Rosenstock J., Shimomura I., Viljoen A., Wadden T.A., et al., STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet., 2021; 397: 971–984 DaviesM. FærchL. JeppesenO.K. PaksereshtA. PedersenS.D. PerreaultL. RosenstockJ. ShimomuraI. ViljoenA. WaddenT.A. STEP 2 Study Group Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial The Lancet 2021 397 971 984 Search in Google Scholar

[11] Rubino D., Abrahamsson N., Davies M., Hesse D., Greenway F.L., Jensen C., Lingvay I., Mosenzon O., Rosenstock J., Rubio M.A., et al., STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults With over-weight or obesity: The STEP 4 randomized clinical trial. JAMA., 2021; 325: 1414–1425 RubinoD. AbrahamssonN. DaviesM. HesseD. GreenwayF.L. JensenC. LingvayI. MosenzonO. RosenstockJ. RubioM.A. STEP 4 Investigators Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults With over-weight or obesity: The STEP 4 randomized clinical trial JAMA 2021 325 1414 1425 Search in Google Scholar

[12] Kadowaki T., Isendahl J., Khalid U., Lee S.Y., Nishida T., Ogawa W., Tobe K., Yamauchi T., Lim S., STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol., 2022 10: 193–206 KadowakiT. IsendahlJ. KhalidU. LeeS.Y. NishidaT. OgawaW. TobeK. YamauchiT. LimS. STEP 6 investigators Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Lancet Diabetes Endocrinol 2022 10 193 206 Search in Google Scholar

[13] Rubino D.M., Greenway F.L., Khalid U., O’Neil P.M., Rosenstock J., Sørrig R., Wadden T.A., Wizert A., Garvey W.T., STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults With overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial. JAMA., 2022; 327: 138–150 RubinoD.M. GreenwayF.L. KhalidU. O’NeilP.M. RosenstockJ. SørrigR. WaddenT.A. WizertA. GarveyW.T. STEP 8 Investigators Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults With overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial JAMA 2022 327 138 150 Search in Google Scholar

[14] Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity, Available at: https://www.prnewswire.com/news-releases/wegovy-demonstrated-significant-and-sustained-weight-loss-in-two-year-study-in-adults-with-obesity-301417583.html (Accessed September 26, 2022) Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity Available at: https://www.prnewswire.com/news-releases/wegovy-demonstrated-significant-and-sustained-weight-loss-in-two-year-study-in-adults-with-obesity-301417583.html (Accessed September 26, 2022) Search in Google Scholar

[15] Wadden T.A., Bailey T.S., Billings L.K., Davies M., Frias J.P., Koroleva A., Lingvay I., O’Neil P.M., Rubino D.M., Skovgaard D., et al., STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with over-weight or obesity: The STEP 3 Randomized Clinical Trial. JAMA., 2021; 325: 1403–1413 WaddenT.A. BaileyT.S. BillingsL.K. DaviesM. FriasJ.P. KorolevaA. LingvayI. O’NeilP.M. RubinoD.M. SkovgaardD. STEP 3 Investigators Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with over-weight or obesity: The STEP 3 Randomized Clinical Trial JAMA 2021 325 1403 1413 Search in Google Scholar

[16] Jabbour S.A., Frías J.P., Guja C., Hardy E., Ahmed A., Öhman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab. czerwiec 2018; 20: 1515–9 JabbourS.A. FríasJ.P. GujaC. HardyE. AhmedA. ÖhmanP. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study Diabetes Obes Metab czerwiec 2018 20 1515 9 Search in Google Scholar

[17] Basu R, Noureddin M, Clark JM. Nonalcoholic fatty liver disease: Review of management for primary care providers. Mayo Clin Proc., wrzesień 2022; 97: 1700–16 BasuR NoureddinM ClarkJM. Nonalcoholic fatty liver disease: Review of management for primary care providers Mayo Clin Proc wrzesień 2022 97 1700 16 Search in Google Scholar

[18] Kosmalski M., Drzewoski J., Szymczak-Pajor I., Zieleniak A., Mikołajczyk-Solińska M., Kasznicki J., Śliwińska A.. Irisin is related to non-alcoholic fatty liver disease (NAFLD). Biomedicines, 2022; 10: 2253 KosmalskiM. DrzewoskiJ. Szymczak-PajorI. ZieleniakA. Mikołajczyk-SolińskaM. KasznickiJ. ŚliwińskaA. Irisin is related to non-alcoholic fatty liver disease (NAFLD) Biomedicines 2022 10 2253 Search in Google Scholar

[19] Cichoż-Lach H. Obesity and non-alcoholic fatty liver disease. In: Clinical Obesitology. Bielsko-Biała: Alfa-Medica Press; 2021: 206–15 Cichoż-LachH. Obesity and non-alcoholic fatty liver disease In: Clinical Obesitology Bielsko-Biała Alfa-Medica Press 2021 206 15 Search in Google Scholar

[20] Ghosal S., Datta D., Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 11 listopad 2021; 11: 22063 GhosalS. DattaD. SinhaB. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D) Sci Rep 11 listopad 2021 11 22063 Search in Google Scholar

[21] Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin., 2008; 24: 275–286 KlonoffD.C. BuseJ.B. NielsenL.L. GuanX. BowlusC.L. HolcombeJ.H. WintleM.E. MaggsD.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 275 286 Search in Google Scholar

[22] Armstrong M.J., Houlihan D.D., Rowe I.A., Clausen W.H., Elbrønd B., Gough S.C., Tomlinson J.W., Newsome P.N. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther., 2013; 37: 234–242 ArmstrongM.J. HoulihanD.D. RoweI.A. ClausenW.H. ElbrøndB. GoughS.C. TomlinsonJ.W. NewsomeP.N. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program Aliment Pharmacol Ther 2013 37 234 242 Search in Google Scholar

[23] Jendle J., Nauck M.A., Matthews D.R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B.J., Garber A.J.; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab., 2009; 11: 1163–72 JendleJ. NauckM.A. MatthewsD.R. FridA. HermansenK. DüringM. ZdravkovicM. StraussB.J. GarberA.J. LEAD-2 and LEAD-3 Study Groups Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue Diabetes Obes Metab 2009 11 1163 72 Search in Google Scholar

[24] Petit J.M., Cercueil J.P., Loffroy R., Denimal D., Bouillet B., Fourmont C., Chevallier O., Duvillard L., Vergès B. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab., 2017;102: 407–415 PetitJ.M. CercueilJ.P. LoffroyR. DenimalD. BouilletB. FourmontC. ChevallierO. DuvillardL. VergèsB. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD Study J Clin Endocrinol Metab 2017 102 407 415 Search in Google Scholar

[25] Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., Hazlehurst J.M., Guo K.; LEAN trial team, Abouda G., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387: 679–690 ArmstrongM.J. GauntP. AithalG.P. BartonD. HullD. ParkerR. HazlehurstJ.M. GuoK. LEAN trial team AboudaG. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Lancet 2016 387 679 690 Search in Google Scholar

[26] Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., Sanyal AJ, Sejling AS, Harrison SA; et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med., 2021; 384: 1113–1124 NewsomeP.N. BuchholtzK. CusiK. LinderM. OkanoueT. RatziuV. SanyalAJ SejlingAS HarrisonSA A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis N Engl J Med 2021 384 1113 1124 Search in Google Scholar

[27] Péterfi Z., Szilvásy-Szabó A., Farkas E., Ruska Y., Pyke C., Knudsen L.B., Fekete C. Glucagon-like peptide-1 regulates the proopiomelanocortin neurons of the arcuate nucleus both directly and indirectly via presynaptic action. Neuroendocrinology, 2021; 111: 986–997 PéterfiZ. Szilvásy-SzabóA. FarkasE. RuskaY. PykeC. KnudsenL.B. FeketeC. Glucagon-like peptide-1 regulates the proopiomelanocortin neurons of the arcuate nucleus both directly and indirectly via presynaptic action Neuroendocrinology 2021 111 986 997 Search in Google Scholar

[28] Müller T.D., Finan B., Bloom S.R., D’Alessio D., Drucker D.J., Flatt P.R., Fritsche A., Gribble F., Grill H.J., Habener J.F., et al. Glucagon-like peptide 1 (GLP-1). Mol Metab., 2019; 30: 72–130 MüllerT.D. FinanB. BloomS.R. D’AlessioD. DruckerD.J. FlattP.R. FritscheA. GribbleF. GrillH.J. HabenerJ.F. Glucagon-like peptide 1 (GLP-1) Mol Metab 2019 30 72 130 Search in Google Scholar

[29] Heppner K.M., Kirigiti M., Secher A., Paulsen S.J., Buckingham R., Pyke C., Knudsen L.B., Vrang N., Grove K.L. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology, 2015; 156: 255–267 HeppnerK.M. KirigitiM. SecherA. PaulsenS.J. BuckinghamR. PykeC. KnudsenL.B. VrangN. GroveK.L. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain Endocrinology 2015 156 255 267 Search in Google Scholar

[30] Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP–1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res., 2011; 89: 481–489 HamiltonA. PattersonS. PorterD. GaultV.A. HolscherC. Novel GLP–1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain J Neurosci Res 2011 89 481 489 Search in Google Scholar

[31] Athauda D., Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today, 2016; 21: 802–818 AthaudaD. FoltynieT. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action Drug Discov Today 2016 21 802 818 Search in Google Scholar

[32] Spielman L.J., Gibson D.L., Klegeris A. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors. Eur J Cell Biol., 2017; 96: 240–253 SpielmanL.J. GibsonD.L. KlegerisA. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors Eur J Cell Biol 2017 96 240 253 Search in Google Scholar

[33] Timper K., Del Río–Martín A., Cremer A.L., Bremser S., Alber J., Giavalisco P., Varela L., Heilinger C., Nolte H., Trifunovic A., et al. GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function. Cell Metab., 2020; 31: 1189–1205.e13 TimperK. Del Río–MartínA. CremerA.L. BremserS. AlberJ. GiavaliscoP. VarelaL. HeilingerC. NolteH. TrifunovicA. GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function Cell Metab 2020 31 1189 1205.e13 Search in Google Scholar

[34] Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, et al. Central and peripheral GLP–1 systems independently suppress eating. Nat Metab. 2021; 3(2): 258–273. BrierleyDI HoltMK SinghA de AraujoA McDougleM VergaraM AfaghaniMH LeeSJ ScottK MaskeC Central and peripheral GLP–1 systems independently suppress eating Nat Metab 2021 3 2 258 273 Search in Google Scholar

[35] Głombik K., Detka J., Budziszewska B. Hormonal regulation of oxidative phosphorylation in the brain in health and disease. Cells, 2021;10: 2937 GłombikK. DetkaJ. BudziszewskaB. Hormonal regulation of oxidative phosphorylation in the brain in health and disease Cells 2021 10 2937 Search in Google Scholar

[36] Farr O.M., Upadhyay J., Rutagengwa C., DiPrisco B., Ranta Z., Adra A., Bapatla N., Douglas V.P., Douglas K.A.A., Nolen-Doerr E., et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab., 2019; 21: 2459–2464 FarrO.M. UpadhyayJ. RutagengwaC. DiPriscoB. RantaZ. AdraA. BapatlaN. DouglasV.P. DouglasK.A.A. Nolen-DoerrE. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies Diabetes Obes Metab 2019 21 2459 2464 Search in Google Scholar

[37] Seghieri M., Rebelos E., Gastaldelli A., Astiarraga B.D., Casolaro A., Barsotti E., Pocai A., Nauck M., Muscelli E., Ferrannini E. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia., 2013; 56: 156–161 SeghieriM. RebelosE. GastaldelliA. AstiarragaB.D. CasolaroA. BarsottiE. PocaiA. NauckM. MuscelliE. FerranniniE. Direct effect of GLP-1 infusion on endogenous glucose production in humans Diabetologia 2013 56 156 161 Search in Google Scholar

[38] Gastaldelli A., Gaggini M., Daniele G., Ciociaro D., Cersosimo E., Tripathy D., Triplitt C., Fox P., Musi N., DeFronzo R., et al. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016; 64: 2028–2037 GastaldelliA. GagginiM. DanieleG. CiociaroD. CersosimoE. TripathyD. TriplittC. FoxP. MusiN. DeFronzoR. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study Hepatology 2016 64 2028 2037 Search in Google Scholar

[39] Gupta N.A., Mells J., Dunham R.M., Grakoui A., Handy J., Saxena N.K., Anania F.A. Glucagon–like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 2010; 51: 1584–1592 GuptaN.A. MellsJ. DunhamR.M. GrakouiA. HandyJ. SaxenaN.K. AnaniaF.A. Glucagon–like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway Hepatology 2010 51 1584 1592 Search in Google Scholar

[40] Pyke C., Heller R.S., Kirk R.K., Ørskov C., Reedtz-Runge S., Kaastrup P., Hvelplund A., Bardram L., Calatayud D., Knudsen L.B. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 2014; 155: 1280–1290 PykeC. HellerR.S. KirkR.K. ØrskovC. Reedtz-RungeS. KaastrupP. HvelplundA. BardramL. CalatayudD. KnudsenL.B. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody Endocrinology 2014 155 1280 1290 Search in Google Scholar

[41] Seghieri M., Christensen A.S., Andersen A., Solini A., Knop F.K., Vilsbøll T. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne), 2018; 9: 649 SeghieriM. ChristensenA.S. AndersenA. SoliniA. KnopF.K. VilsbøllT. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD Front Endocrinol (Lausanne) 2018 9 649 Search in Google Scholar

[42] Svegliati-Baroni G., Saccomanno S., Rychlicki C., Agostinelli L., De Minicis S., Candelaresi C., Faraci G., Pacetti D., Vivarelli M., Nicolini D., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int., 2011; 31: 1285–1297 Svegliati-BaroniG. SaccomannoS. RychlickiC. AgostinelliL. De MinicisS. CandelaresiC. FaraciG. PacettiD. VivarelliM. NicoliniD. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 2011 31 1285 1297 Search in Google Scholar

[43] Oliveira F.C.B., Bauer E.J., Ribeiro C.M., Pereira S.A., Beserra B.T.S., Wajner S.M., Maia A.L., Neves F.A.R., Coelho M.S., Amato A.A. Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue. Front Endocrinol (Lausanne). 2022; 12: 803363 OliveiraF.C.B. BauerE.J. RibeiroC.M. PereiraS.A. BeserraB.T.S. WajnerS.M. MaiaA.L. NevesF.A.R. CoelhoM.S. AmatoA.A. Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue Front Endocrinol (Lausanne) 2022 12 803363 Search in Google Scholar

[44] Marín-Juez R., Jong-Raadsen S., Yang S., Spaink H.P. Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafish. J Endocrinol., 2014; 222: 229–241 Marín-JuezR. Jong-RaadsenS. YangS. SpainkH.P. Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafish J Endocrinol 2014 222 229 241 Search in Google Scholar

[45] Lu Y., Jiang Z., Dai H., Miao R., Shu J., Gu H., Liu X., Huang Z., Yang G., Chen A.F., et al. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway. Hepatology. 2018; 67: 1303–1319 LuY. JiangZ. DaiH. MiaoR. ShuJ. GuH. LiuX. HuangZ. YangG. ChenA.F. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway Hepatology 2018 67 1303 1319 Search in Google Scholar

[46] Xu E., Forest M.P., Schwab M., Avramoglu R.K., St-Amand E., Caron A.Z., Bellmann K., Shum M., Voisin G., Paquet M., et al. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ. Hepatology, 2014; 59: 1803–1815 XuE. ForestM.P. SchwabM. AvramogluR.K. St-AmandE. CaronA.Z. BellmannK. ShumM. VoisinG. PaquetM. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ Hepatology 2014 59 1803 1815 Search in Google Scholar

[47] Yu P., Xu X., Zhang J., Xia X., Xu F., Weng J., Lai X., Shen Y. Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathway. Int J Endocrinol., 2019; 19: 1567095 YuP. XuX. ZhangJ. XiaX. XuF. WengJ. LaiX. ShenY. Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathway Int J Endocrinol 2019 19 1567095 Search in Google Scholar

[48] Kim E.R., Park J.S., Kim J.H., Oh J.Y., Oh I.J., Choi D.H., Lee Y.S., Park I.S., Kim S., Lee D.H., et al. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. Hepatology, 2022; 75: 1523–1538 KimE.R. ParkJ.S. KimJ.H. OhJ.Y. OhI.J. ChoiD.H. LeeY.S. ParkI.S. KimS. LeeD.H. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome Hepatology 2022 75 1523 1538 Search in Google Scholar